

Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis Clinical Trial

PROTOCOL NUMBER: GS-US-300-0128	
STUDY NAME: ARTEMIS-PH	
Official Title	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of <u>A</u> mbri <u>s</u> entan in Subjects with Idiopathic Pul <u>m</u> onary Fi <u>b</u> rosis and Pulmonary <u>H</u> ypertension
Purpose	The purpose of this study is to assess the safety and effectiveness of ambrisentan in subjects with Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF).
Investigational Drug	Ambrisentan
Select Inclusion Criteria	<ul style="list-style-type: none"> • Diagnosis of Idiopathic Pulmonary Fibrosis(IPF) as defined by protocol-specific criteria • Diagnosis of PH on RHC, defined by the following hemodynamic criteria: <ul style="list-style-type: none"> ○ mPAP of ≥ 25 mmHg ○ PVR >240 dyne\cdotsec/cm⁵ ○ PCWP or LVEDP of ≤ 15 mmHg ○ RHC performed within 24 weeks prior to the Screening are acceptable, if longer than 24 weeks, the RHC must to be repeated. • Forced vital capacity (FVC) $\geq 40\%$ at Screening
Status	Open to enrollment
Contact Information	Research Coordinator: Edwinia Battle, RN - Ph: 703-776-3067, email: edwinia.battle@inova.org Principal Investigator: Steven Nathan, MD